Bailard Inc. boosted its holdings in shares of Zogenix, Inc. (NASDAQ:ZGNX) by 40,000.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,100 shares of the company’s stock after acquiring an additional 40,000 shares during the period. Bailard Inc.’s holdings in Zogenix were worth $1,989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Schwab Charles Investment Management Inc. grew its holdings in Zogenix by 10.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 76,934 shares of the company’s stock worth $3,401,000 after acquiring an additional 7,537 shares in the last quarter. BlackRock Inc. grew its holdings in Zogenix by 12.4% during the 2nd quarter. BlackRock Inc. now owns 2,939,543 shares of the company’s stock worth $129,928,000 after acquiring an additional 324,650 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Zogenix by 761.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,534,645 shares of the company’s stock worth $67,831,000 after acquiring an additional 1,356,428 shares in the last quarter. First Trust Advisors LP bought a new position in Zogenix during the 2nd quarter worth about $1,292,000. Finally, Swiss National Bank grew its holdings in Zogenix by 5.3% during the 2nd quarter. Swiss National Bank now owns 59,600 shares of the company’s stock worth $2,634,000 after acquiring an additional 3,000 shares in the last quarter.

Several research analysts have issued reports on the stock. Leerink Swann reiterated an “outperform” rating on shares of Zogenix in a report on Friday, October 19th. Zacks Investment Research upgraded shares of Zogenix from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Thursday, October 25th. Mizuho reiterated a “buy” rating and set a $69.00 target price on shares of Zogenix in a report on Thursday. ValuEngine cut shares of Zogenix from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Finally, Stifel Nicolaus assumed coverage on shares of Zogenix in a report on Wednesday, August 15th. They set a “buy” rating and a $69.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $70.00.

NASDAQ:ZGNX opened at $43.61 on Friday. Zogenix, Inc. has a fifty-two week low of $33.42 and a fifty-two week high of $62.75. The stock has a market capitalization of $1.84 billion, a PE ratio of -10.85 and a beta of 1.84.

Zogenix (NASDAQ:ZGNX) last released its quarterly earnings results on Thursday, November 8th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.20). During the same quarter last year, the company posted ($1.68) EPS. On average, sell-side analysts predict that Zogenix, Inc. will post -3.84 earnings per share for the current fiscal year.

In other news, EVP Gail M. Farfel sold 6,961 shares of the firm’s stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $43.23, for a total value of $300,924.03. Following the sale, the executive vice president now directly owns 14,104 shares in the company, valued at approximately $609,715.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Erle T. Mast sold 1,468 shares of the firm’s stock in a transaction dated Monday, November 26th. The shares were sold at an average price of $42.08, for a total transaction of $61,773.44. Following the completion of the sale, the director now owns 3,027 shares in the company, valued at $127,376.16. The disclosure for this sale can be found here. 5.00% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/bailard-inc-acquires-40000-shares-of-zogenix-inc-zgnx/2666552.html.

About Zogenix

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

See Also: What is Cost of Debt?

Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.